NCT04925648View on ClinicalTrials.gov

Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction

PHASE2RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 18, 2021

Primary Completion Date

September 1, 2025

Study Completion Date

December 1, 2025

Conditions
Metastatic Prostate Cancer
Interventions
DRUG

Dasatinib

Dasatinib 100mg once daily orally for 14 Days

DRUG

Darolutamide

Darolumatide 600 mg twice daily orally for 14 Days

Trial Locations (2)

2010

RECRUITING

Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney

3000

NOT_YET_RECRUITING

Peter MacCallum Cancer Centre, Melbourne

All Listed Sponsors
lead

St Vincent's Hospital, Sydney

OTHER